Myelofibrosis: biology and treatment options.
Cervantes
Francisco
F
Haematology Department, Hospital Clínic, Barcelona, Spain. fcervan@clinic.ub.es
D001549:Benzamides; D002908:Chronic Disease; D000068256:Darbepoetin alfa; D004921:Erythropoietin / Q000031:analogs & derivatives / Q000627:therapeutic use; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D006918:Hydroxyurea / Q000627:therapeutic use; D000068877:Imatinib Mesylate; D016898:Interferon-alpha / Q000627:therapeutic use; D010879:Piperazines / Q000627:therapeutic use; D055728:Primary Myelofibrosis / Q000188:drug therapy / Q000503:physiopathology / Q000628:therapy*; D011505:Protein-Tyrosine Kinases / Q000037:antagonists & inhibitors; D011743:Pyrimidines / Q000627:therapeutic use; D011799:Quinazolines / Q000627:therapeutic use; D011994:Recombinant Proteins; D013156:Splenectomy; D013792:Thalidomide / Q000008:administration & dosage / Q000627:therapeutic use
D001549:Benzamides; D016898:Interferon-alpha; D010879:Piperazines; D011743:Pyrimidines; D011799:Quinazolines; D011994:Recombinant Proteins; D004921:Erythropoietin; D000068256:Darbepoetin alfa; D013792:Thalidomide; D000068877:Imatinib Mesylate; D011505:Protein-Tyrosine Kinases; C021139:anagrelide; D006918:Hydroxyurea